You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

platinum sensitive ovarian cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer Trial in Los Angeles (Simvastatin 40mg)

Recruiting
  • Recurrent Ovarian Cancer
  • Platinum-sensitive Ovarian Cancer
  • Simvastatin 40mg
  • Los Angeles, California
    Cedars Sinai Medical Center
Apr 21, 2022

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (ribociclib, Paclitaxel, Carboplatin)

Completed
  • Ovarian Cancer
  • +2 more
  • Ann Arbor, Michigan
  • +7 more
Sep 1, 2022

Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)

Terminated
Has Results
  • Platinum Sensitive Ovarian Cancer
  • Ovarian Cancer
  • FRα peptide plus Adjuvant (GM-CSF)
  • Adjuvant (GM-CSF) Alone
  • Birmingham, Alabama
  • +17 more
Nov 21, 2022

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)

Not yet recruiting
  • Ovarian Cancer
  • Malignant Neoplasm of Uterus
  • New York, New York
    Icahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Fuzuloparib Combination with Bevacizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Cente
Apr 14, 2023

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer Trial (Carboplatin)

Not yet recruiting
  • Ovarian Cancer
  • +6 more
  • (no location specified)
Oct 27, 2022

Ovarian Cancer Trial in Villejuif (AsiDNA, Niraparib, Olaparib)

Recruiting
  • Ovarian Cancer
  • Villejuif, Val De Marne, France
    Gustave Roussy
Sep 27, 2021

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

A Real-World Patient-Reported Outcomes Study in Long-Term Use of

Recruiting
  • Ovarian Cancer
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Sep 13, 2023

    Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

    Recruiting
    • Ovarian Cancer
    • fluzopanib and bevacizumab
    • Chongqing, Chongqing, China
      Chongqing Cancer Hospital
    Sep 19, 2022

    Variance of HRD From Paired Ovarian Cancer

    Not yet recruiting
    • Ovarian Cancer
    • +2 more
      • Nanjing, Jiangsu, China
        Xiaoxiang Chen
      Sep 25, 2021

      Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV Trial in Seoul (Oregovomab, Bevacizumab,

      Recruiting
      • Ovarian Cancer by FIGO Stage
      • +2 more
      • Oregovomab
      • +3 more
      • Daegu, Korea, Republic of
      • +5 more
      Oct 20, 2022

      Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemo, Platinum Sensitive Trial in China,

      Active, not recruiting
      • Relapsed Ovarian Cancer
      • +2 more
      • Olaparib 300mg tablets
      • Beijing, China
      • +24 more
      Dec 5, 2022

      Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer Trial in France (OSE2101, Pembrolizumab 25 MG/ML [Keytruda])

      Recruiting
      • Platinum-sensitive Ovarian Cancer
      • Relapsed Ovarian Cancer
      • OSE2101
      • Pembrolizumab 25 MG/ML [Keytruda]
      • Angers, France
      • +27 more
      Jul 25, 2022

      Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma

      Recruiting
      • Recurrent Ovarian Cancer
      • +6 more
      • Durham, North Carolina
      • +2 more
      Jul 26, 2022

      Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer Trial in Czechia, Poland (RP12146)

      Recruiting
      • Solid Tumor
      • +6 more
      • Hořovice, Czechia
      • +5 more
      Jun 8, 2022

      OVARIAN CANCER Trial in Worldwide (Cobimetinib, Niraparib, Atezolizumab)

      Recruiting
      • OVARIAN CANCER
      • Tucson, Arizona
      • +28 more
      Jan 10, 2023

      Relapsed Ovarian Cancer Trial (Fluzoparib+Apatinib, Fluzoparib Monotherapy)

      Not yet recruiting
      • Relapsed Ovarian Cancer
      • (no location specified)
      Jul 27, 2022

      Ovarian Cancer Trial in Manchester (Olaparib, Cediranib, Platinum-based Chemotherapy)

      Completed
      • Ovarian Cancer
      • Manchester, United Kingdom
        The Christie NHS Foundation Trust
      Feb 4, 2022

      Ovarian Cancer, Breast Cancer Trial in India (Olaparib)

      Completed
      • Ovarian Cancer
      • Breast Cancer
      • Ahmedabad, India
      • +15 more
      Oct 28, 2022